Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:51 AM
Ignite Modification Date:
2025-12-24 @ 11:51 AM
NCT ID:
NCT00794261
Eligibility Criteria:
Inclusion Criteria:
* Male or female patients aged ≥ 18 years
* Patients with histologically confirmed lymphoma or myeloma
* Treatment with high-dose chemotherapy before inclusion
* Intensification with high dose Melphalan for patients with myeloma
* Whatever the conditioning regimen, except TBI for patients with 1st relapse of Hodgkin's lymphoma or with MNHL NB: Patients having received two intensification courses are eligible if there has been more than 100 days between courses.
* Autologous PSC transplantation at the time of inclusion
* Reinjection of ≥ 2.106 CD34/kg
* Patients hospitalized in the investigator center throughout the procedure until recovery from aplasia (PNN \> 0.5 G/L)
* Mandatory affiliation with a health insurance system
* Patients able to understand, read and write French
* Signed, written informed consent
Exclusion Criteria:
* TBI during conditioning
* Severe intolerance to the growth factor under study, or hypersensitivity to one of their components
* Immunosuppressive syndrome
* Pregnant or lactating women
* Difficult follow-up
* Documented history of cognitive or psychiatric disorders
* Participation or consideration of participation in another biomedical study during the follow-up period of the present trial.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00794261
Study Brief:
Protocol Section:
NCT00794261